英文互译镜像站

Bortezomib/dexamethasone
Combination of
Bortezomib	Proteasome inhibitor
Dexamethasone	Corticosteroid
Clinical data
Trade names	Vel/Dexm, Vel-Dex, and Veldex
Legal status
Legal status	US: ℞-only ;

Bortezomib/dexamethasone

Last updated June 24, 2025

Bortezomib/dexamethasone is a combination drug against multiple myeloma.^[1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid.

References

↑ Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, et al. (February 2010). "Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma". Leukemia & Lymphoma. 51 (2): 236–42. doi:10.3109/10428190903452826. PMID 20001242. S2CID 25932724.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

自动镜像站群镜像网站程序镜像精灵小偷程序量子镜像站群

[CorsoBarbarano2009-1] Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, et al. (February 2010). "Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma". Leukemia & Lymphoma. 51 (2): 236–42. doi:10.3109/10428190903452826. PMID 20001242. S2CID 25932724.

[1]